ERBB2-targeted therapies are the standard of care in clinical practice guidelines for the treatment of ERBB2-positive breast cancer.42 Previous studies have suggested that treatment delays of 3 to 6 months are associated with worse survival in individuals with breast cancer.43,44 Thus, the years-long disparities between Black and White and Hispanic and White patients in ERBB2 therapy initiation between 2010-2011 and 2018-2019 may have resulted in poor clinical outcomes, including a widening of the mortality gap, among racially and ethnically minoritized populations with breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.